Hepatitis C: Have we Found the Right Formula? |
Conferences
eMediNexus Coverage from: 
Hepatitis C: Have we Found the Right Formula?
Dr Paul J Thuluvath, Baltimore,  05 December 2018
Coronavirus Live Count Map India

remove_red_eye 781 Views
COVID-19 Vaccine Updates

Coronavirus Protocols

#Gastroenterology #Nephrology

0 Read Comments                

Limitations of pangenotypic drugs:Sofosbuvir + velpatasvir for 12 weeks (contraindicated when GFR < 30 ml)Glecaprevir + pibrentasvir for 8-12 weeks (safe in renal failure and dialysis, but unsafe in child B and child C cirrhosis)Sofosbuvir + velpatasvir + voxilaprevir for 12 weeks (For DAA failures, contraindicated with GFR < 30 ml)National guidelines in India in:Treatment naïve HCV without cirrhosis: Sofosbuvir (400 mg) + daclatasvir (60 mg) for 12 weeksTreatment naïve HCV with ...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now